Withaferin A suppresses malignant progression of leukemia by reducing promoter methylation levels

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with limited effective treatment options. Withaferin A, a steroidal lactone derived from Withania somnifera, has demonstrated broad anticancer activity across various tumor models. Emerging evidence suggests its potential to modulate DNA methylation and to suppress malignant behaviors, though the underlying mechanisms have so far remained unclear. In this study, an in-depth investigation of the pharmacological effects of withaferin A in T-ALL was conducted, focusing on its epigenetic regulatory role. Cytotoxicity assays showed that withaferin A exhibited the strongest activity among its analogs, particularly against CCRF-CEM cells. Through the integration of bioinformatics, network pharmacology, and functional cell experiments, it was found that withaferin A induces G2/M cell cycle arrest, promotes apoptosis, inhibits migration, and suppresses microtubule polymerization in T-ALL cells. Luciferase reporter experiments further confirmed that withaferin A decreases methylation of the CMV promoter. Also, withaferin A alters the expression levels of P21, ITPKB, RAD21, PRR11, AFMID, CCDC34, and CYB5R1 in CCRF-CEM cells. In conclusion, our study provides comprehensive evidence that withaferin A suppresses the malignant progression of T-ALL by modulating DNA methylation levels. The study delivers novel evidence for its role in DNA methylation and lays an experimental foundation for its potential clinical application in T-cell acute lymphoblastic leukemia.

Authors

Institutions

Publication Details

Journal
Cell Death Discovery
Published
2026-11-13
DOI
https://doi.org/10.1038/s41420-026-03435-x
Primary Topic
Phytochemicals and Medicinal Plants
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Withaferin A suppresses malignant progression of leukemia by reducing promoter methylation levels

Mohamed‐Elamir F. Hegazy, Paola Barbara Arimondo, Thomas Efferth, Gerhard Bringmann et al.
2 links
Cell Death Discovery
Phytochemicals and Medicinal Plants
article

Withaferin A suppresses malignant progression of leukemia by reducing promoter methylation levels

Mohamed‐Elamir F. Hegazy, Paola Barbara Arimondo, Thomas Efferth, Gerhard Bringmann, A. A. Leslie Gunatilaka, Sabine M. Klauck, Mohamed Elbadawi, Mona Dawood, Dongxiao Li, Chunmei Jin, Xiao Lei
article en

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with limited effective treatment options. Withaferin A, a steroidal lactone derived from Withania somnifera, has demonstrated broad anticancer activity across various tumor models. Emerging evidence suggests its potential to modulate DNA methylation and to suppress malignant behaviors, though the underlying mechanisms have so far remained unclear. In this study, an in-depth investigation of the pharmacological effects of withaferin A in T-ALL was conducted, focusing on its epigenetic regulatory role. Cytotoxicity assays showed that withaferin A exhibited the strongest activity among its analogs, particularly against CCRF-CEM cells. Through the integration of bioinformatics, network pharmacology, and functional cell experiments, it was found that withaferin A induces G2/M cell cycle arrest, promotes apoptosis, inhibits migration, and suppresses microtubule polymerization in T-ALL cells. Luciferase reporter experiments further confirmed that withaferin A decreases methylation of the CMV promoter. Also, withaferin A alters the expression levels of P21, ITPKB, RAD21, PRR11, AFMID, CCDC34, and CYB5R1 in CCRF-CEM cells. In conclusion, our study provides comprehensive evidence that withaferin A suppresses the malignant progression of T-ALL by modulating DNA methylation levels. The study delivers novel evidence for its role in DNA methylation and lays an experimental foundation for its potential clinical application in T-cell acute lymphoblastic leukemia.

Cell Death DiscoveryVol. 12(1)
Centre National de la Recherche Scientifique (FR), University of Arizona (US), Institut Pasteur (FR), Johannes Gutenberg University Mainz (DE), Université Paris Cité (FR), Heidelberg University (DE), University of Würzburg (DE), University Hospital Heidelberg (DE), National Center for Tumor Diseases (DE), Epigénétique et Destin Cellulaire (FR), National Research Centre (EG)
Alexander von Humboldt-Stiftung, Deutsches Krebsforschungszentrum, China Scholarship Council
Good health and well-being
Phytochemicals and Medicinal Plants
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon